Topics
oncologyMedical specialty
The advancement of therapeutic strategies in oncology such as precision oncology has generated significant interest in better estimating the response of modern phase I cancer clinical trials. These estimates have varied widely. In this commentary, we provide an umbrella review of phase I response rates and discuss methodological reasons for variation in prior estimates which include limited use of unpublished data, the inclusion of expansion cohorts that artificially raise response rates of cumulative response rates, varying enrolment of haematologic malignancies, and increased next in class drugs
Because a dose-response relationship is characteristic of conventional chemotherapy, this concept is...
We appreciate the thoughtful commentaries on our article concerning the appraisal of benefit in phas...
The oncology clinical trials are evolving in the era of cancer immunotherapy. In Phase I trials, som...
Early clinical trials of a novel oncology agent or combination regimen usually examine the biologic ...
For many years, oncology phase I trials have been referred to as 'toxicity trials' and have bee...
In this issue of EJC, Perez-Gracia and colleagues question the need for confirmation of response rep...
Previous estimates of the likelihood of a drug tested in phase I trials obtaining FDA clearance are ...
Historically, phase II trials in oncology were generally single armed, constructed to distinguish be...
Introduction. A survey was sent to referring oncologists (ROs) to explore the reasons behind their r...
Most proposals to modify phase I trial designs address one of several issues: patient safety, patien...
International audienceA main criterion to identify activity in phase II studies is the response rate...
textabstractMost anticancer agents developed over the last four decades are cytotoxic drugs inducin...
An efficient phase I trial is a crucial step in developing a new drug in a safe and timely manner. T...
Background: The primary goal of phase I studies is to effi-ciently and accurately determine the reco...
Phase II clinical trials of experimental treatments play an essential role in drug development. Hist...
Because a dose-response relationship is characteristic of conventional chemotherapy, this concept is...
We appreciate the thoughtful commentaries on our article concerning the appraisal of benefit in phas...
The oncology clinical trials are evolving in the era of cancer immunotherapy. In Phase I trials, som...
Early clinical trials of a novel oncology agent or combination regimen usually examine the biologic ...
For many years, oncology phase I trials have been referred to as 'toxicity trials' and have bee...
In this issue of EJC, Perez-Gracia and colleagues question the need for confirmation of response rep...
Previous estimates of the likelihood of a drug tested in phase I trials obtaining FDA clearance are ...
Historically, phase II trials in oncology were generally single armed, constructed to distinguish be...
Introduction. A survey was sent to referring oncologists (ROs) to explore the reasons behind their r...
Most proposals to modify phase I trial designs address one of several issues: patient safety, patien...
International audienceA main criterion to identify activity in phase II studies is the response rate...
textabstractMost anticancer agents developed over the last four decades are cytotoxic drugs inducin...
An efficient phase I trial is a crucial step in developing a new drug in a safe and timely manner. T...
Background: The primary goal of phase I studies is to effi-ciently and accurately determine the reco...
Phase II clinical trials of experimental treatments play an essential role in drug development. Hist...
Because a dose-response relationship is characteristic of conventional chemotherapy, this concept is...
We appreciate the thoughtful commentaries on our article concerning the appraisal of benefit in phas...
The oncology clinical trials are evolving in the era of cancer immunotherapy. In Phase I trials, som...
Add to ORKG